CEL-SCI to Present at the 2014 BIO International Convention
June 18 2014 - 9:00AM
Business Wire
CEL-SCI Corporation (NYSE MKT: CVM) announced that Geert
Kersten, Chief Executive Officer, will be presenting at the 2014
BIO International Convention on Wednesday, June 25th, at 2:00 p.m.
PDT. Hosted by the Biotechnology Industry Organization (BIO), this
year’s global event for biotechnology will take place June 23-26 at
the San Diego Convention Center in San Diego, California.
About the BIO International Convention
The BIO International Convention will highlight the latest
trends and the newest opportunities for executives, investors,
scientists, policy leaders, and media from around the world.
Speakers at the sessions will share breakthroughs in medicine,
diagnostics, the environment, energy production, business
operations, financing, partnerships, policy issues and food and
agriculture. The Convention also features the BIO Business Forum, a
unique platform for biotechnology and pharmaceutical companies,
academic research institutions, and investors from around the world
to gather and discuss strategic opportunities. For registration,
conference agenda and exhibitor information, visit
convention.bio.org/.
About CEL-SCI Corporation
CEL-SCI’s work is focused on finding the best way to activate
the immune system to fight cancer and infectious diseases. Its lead
investigational therapy Multikine (Leukocyte Interleukin,
Injection) is currently being studied in a pivotal Phase III
clinical trial against head and neck cancer. If the study endpoint,
which is a 10% improvement in overall survival of the subjects
treated with Multikine treatment regimen as compared to subjects
treated with current standard of care only is satisfied, the study
results will be used to support applications which will be
submitted to regulatory agencies in order to receive from these
agencies commercial marketing approvals for Multikine in major
markets around the world. Additional clinical indications for
Multikine which are being investigated include cervical dysplasia
in HIV/HPV co-infected women, and the treatment of peri-anal warts
in HIV/HPV co-infected men and women. A Phase I trial of the former
indication has been completed at the University of Maryland. The
latter indication is now in a Phase I trial in conjunction with the
U.S. Navy under a CRADA (Cooperative Research and Development
Agreement).
CEL-SCI is also developing its LEAPS technology for the
treatment of pandemic influenza and as a potential therapeutic
vaccine against rheumatoid arthritis. The Company has operations in
Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024